Tone mix
Week by week 52 weeks
Share of Amgen Inc's 803 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of May 11, 2026 · tone +75Amgen Touts Repatha Growth, MariTide Potential and 2026 'Springboard' at Conference+53
- Week of Jun 29, 2026 · tone -37Amgen Inc. faces recall of Corlanor and Sensipar medications-36
- Week of Apr 13, 2026 · tone +62Amgen (NASDAQ:AMGN) Price Target Raised to $351.00+34
- Week of May 18, 2026 · tone -19Amgen's rare disease drug linked to deaths, liver injuries in Japan-32
- Week of Feb 23, 2026 · tone -5Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate-28
- Week of Mar 30, 2026 · tone -5FDA Warns Of Fatal Liver Risks Linked To Amgen Tavneos Use - Amgen (NASDAQ:AMGN)-28
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Amgen Inc in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 31 | +42 |
| Last 30 sessions | 65 | +21 |
| Last 90 sessions | 235 | +11 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
2 headlines, average tone +50: 1 positive, 1 neutral and 0 negative. Showing all 2.
- baystreet.ca · 1 outletBaystreet.ca - Total Energy, ACT, Amgen at 52-Week Highs on NewsPositive
- www.prnewswire.com · 1 outletAMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTSNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Baystreet.ca - Total Energy, ACT, Amgen at 52-Week Highs on News | baystreet.ca | 1 | Positive |
| AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 28, 2026
5 headlines, average tone +20: 1 positive, 4 neutral and 0 negative. Showing all 5.
- www.investors.com · 2 outletsDow Jones Biotech Giant Amgen Stock Breaks Out | Investor's Business DailyPositive
- www.fool.com · 2 outletsAmgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug RevenueNeutral
- www.fool.com · 2 outletsAmgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?Neutral
- www.prnewswire.com · 1 outletAMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDENDNeutral
- www.prnewswire.com · 1 outletAMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026Neutral
Show the table · 5 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Dow Jones Biotech Giant Amgen Stock Breaks Out | Investor's Business Daily | www.investors.com | 2 | Positive |
| Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue | www.fool.com | 2 | Neutral |
| Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? | www.fool.com | 2 | Neutral |
| AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND | www.prnewswire.com | 1 | Neutral |
| AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 27, 2026
6 headlines, average tone +60: 4 positive, 2 neutral and 0 negative. Showing all 6.
- www.thehindu.com · 1 outletAmgen drug combined with immunotherapy extends survival in lung cancer trialPositive
- www.rttnews.com · 1 outletAmgen And AstraZeneca's IMDELLTRA Plus IMFINZI Cuts Death Risk By 58% In Small Cell Lung CancerPositive
- www.2minutemedicine.com · 1 outletTarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 resultsPositive
- www.biopharmadive.com · 1 outletESMO '26: A cancer vaccine debate, Roche's KRAS progress and Amgen's 'unprecedented' dataPositive
- econotimes.com · 1 outletAmgen Adds Former Yum! Brands CEO David Gibbs to Its BoardNeutral
- www.prnewswire.com · 1 outletAMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORSNeutral
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Amgen drug combined with immunotherapy extends survival in lung cancer trial | www.thehindu.com | 1 | Positive |
| Amgen And AstraZeneca's IMDELLTRA Plus IMFINZI Cuts Death Risk By 58% In Small Cell Lung Cancer | www.rttnews.com | 1 | Positive |
| Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results | www.2minutemedicine.com | 1 | Positive |
| ESMO '26: A cancer vaccine debate, Roche's KRAS progress and Amgen's 'unprecedented' data | www.biopharmadive.com | 1 | Positive |
| Amgen Adds Former Yum! Brands CEO David Gibbs to Its Board | econotimes.com | 1 | Neutral |
| AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
12 headlines, average tone +54: 7 positive, 4 neutral and 1 negative. The 8 most widely carried stories are listed; the table holds all 12.
- www.tickerreport.com · 2 outletsAmgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer StudyPositive
- www.aol.com · 2 outletsAbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?Negative
- www.aol.com · 2 outletsAmgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?Neutral
- www.fool.com · 2 outletsAmgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?Neutral
- www.gdnonline.com · 1 outletHealth: Amgen drug combined with immunotherapy extends survival in lung cancer trialPositive
- arynews.tv · 1 outletAmgen drug combined with immunotherapy extends survival in lung cancer trialPositive
- www.thenews.com.pk · 1 outletNew Amgen drug combination shows survival gains in lung cancer trialPositive
- bdnews24.com · 1 outletAmgen drug paired with immunotherapy improves survival in lung cancer trial: reportPositive
Show the table · 12 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study | www.tickerreport.com | 2 | Positive |
| AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's? | www.aol.com | 2 | Negative |
| Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? | www.aol.com | 2 | Neutral |
| Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? | www.fool.com | 2 | Neutral |
| Health: Amgen drug combined with immunotherapy extends survival in lung cancer trial | www.gdnonline.com | 1 | Positive |
| Amgen drug combined with immunotherapy extends survival in lung cancer trial | arynews.tv | 1 | Positive |
| New Amgen drug combination shows survival gains in lung cancer trial | www.thenews.com.pk | 1 | Positive |
| Amgen drug paired with immunotherapy improves survival in lung cancer trial: report | bdnews24.com | 1 | Positive |
| Amgen-AstraZeneca drug combination cut risk of death in small cell lung cancer by 58% | www.moneycontrol.com | 1 | Positive |
| Amgen's Imdelltra combo cuts risk of death by 58% in lung cancer | www.cnbc.com | 1 | Positive |
| Amgen Inc. $AMGN Shares Newly Purchased by Vision Financial Markets LLC | www.themarketsdaily.com | 1 | Neutral |
| Amgen Says Sustainability Is A Companywide Commitment | Investor's Business Daily | www.investors.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
2 headlines, average tone +44: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.fool.com · 2 outletsAmgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?Neutral
- csrwire.com · 1 outletAmgen Foundation Tops $75 Million in Hands-On Biotechnology Education, Reaching 100,000 Students a YearPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? | www.fool.com | 2 | Neutral |
| Amgen Foundation Tops $75 Million in Hands-On Biotechnology Education, Reaching 100,000 Students a Year | csrwire.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Amgen Inc, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.